Clinical trials: Dysmenorrhea Primary
Dysmenorrhea
Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)
The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).
- Trial name
- Lidocaine 04 (NCT00651313)
- Testing
- Lidocaine
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Dysmenorrhea
Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea
The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.
- Trial name
- NCT01250587
- Testing
- PDC31
- Where
- 4 sites in Austria, Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PDC Biotech GmbH
Dysmenorrhea
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.
- Trial name
- NCT00649415
- Testing
- piroxicam, valdecoxib
- Where
- 10 sites in Brazil
- Volunteers
- 154 people
- Sponsor
- Pfizer
Primary Dysmenorrhea
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses.
- Trial name
- NCT06317064
- Testing
- Ibuprofen and Aprepitant
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lahore Medical Research Center, LLP
Dysmenorrhea
Drotaverine in Dysmenorrhoea Treatment
The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and…
- Trial name
- NCT00292747
- Testing
- Drotaverine, Ibuprofen
- Where
- Hungary
- Volunteers
- 480 people
- Sponsor
- Sanofi
Primary Dysmenorrhea
Effect of KYG0395 on Primary Dysmenorrhea
The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.
- Trial name
- NCT01588236
- Testing
- high dose KYG0395, lower dose KYG0395
- Where
- 23 sites in United States
- Volunteers
- 280 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Primary Dysmenorrhea
Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea
A Multi-center, Randomized, Placebo-controlled, Double-blind, Cross-over, Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients with Primary Dysmenorrhea
- Trial name
- NCT04541134
- Testing
- Pelubiprofen 45mg
- Volunteers
- 120 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Primary Dysmenorrhea
Effect on Primary Dysmenorrhea
To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.
- Trial name
- NCT00909857
- Testing
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova)
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Bayer
Dysmenorrhea
A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
The purpose of this study is to compare the maximum single dose of Aleve® (two tablets, equivalent to 440 mg of naproxen sodium) to the maximum single dose of Tylenol Extra Strength (two caplets, equivalent to 1000 mg of…
- Trial name
- NCT03448536
- Testing
- Naproxen Sodium, (Aleve, BAY117031), Acetaminophen (Tylenol Extra Strength)
- Where
- 8 sites in United States
- Volunteers
- 201 people
- Sponsor
- Bayer
Dysmenorrhea
The Effectiveness and Safety of LIVIA® Transcutaneous Electrical Nerve Stimulation (TENS) in Women Suffering From Primary Dysmenorrhea.
This is a randomized, controlled, multi-center, single-arm, crossover, double-blind clinical study assessing the Livia Transcutaneous Electrical Nerve Stimulation (TENS) in women suffering from dysmenorrhea.
- Trial name
- NCT03064945
- Testing
- Livia
- Where
- Israel
- Volunteers
- 63 people
- Sponsor
- iPulse Medical Ltd. (Livia)
Dysmenorrhea
A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
The study investigates four vaginal ring groups with respect to relief of primary dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant treatment efficacy in relief of primary dysmenorrhea.
- Trial name
- NCT01670656
- Testing
- Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR), Etonogestrel containing contraceptive vaginal ring (ENG-CVR), Ibuprofen
- Volunteers
- 439 people
- Sponsor
- Organon and Co
Primary Dysmenorrhea
Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
- Trial name
- ASTRAL (NCT05640232)
- Testing
- CDE100 association, Buscopan® Composto association
- Where
- Brazil
- Volunteers
- 238 people
- Sponsor
- EMS
Dysmenorrhea
Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
This is a study to determine the overall analgesic effect of a single oral dose of etoricoxib compared to ibuprofen in participants with moderate-to-severe primary dysmenorrhea.
- Trial name
- NCT01462370
- Testing
- Etoricoxib, Ibuprofen, Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
- Volunteers
- 139 people
- Sponsor
- Organon and Co